Venom immunotherapy in patients with mastocytosis

ConclusionsPatients with primary MCAS and IgE-mediated HVA are candidates to receive VIT. Their management does not differ much from general population with the exception of VIT duration.
Source: Allergo Journal International - Category: Allergy & Immunology Source Type: research